| http://www.w3.org/ns/prov#value | - SAN DIEGO, July 31, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the two most recent hepatitis c (HCV) infected patients to receive Hemopurifier?? therapy in combination with peginterferon+ribavirin (PR) drug therapy achiev
|
